Results of the votes of the combined shareholders' general meeting of may 22, 2025

Daix (france), new york city (new york, united states), may 23, 2025 – inventiva (euronext paris and nasdaq: iva) (the “company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), today announced the results of the votes of its combined shareholders' meeting.
GM Ratings Summary
GM Quant Ranking